CVKD · Cadrenal Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | - | - | $220.1K | $220.1K |
| Gross Profit | - | - | - | - |
| R&D | $4.10M | $4.21M | $4.08M | $136.8K |
| SG&A | $9.35M | $6.75M | $3.55M | $2.31M |
| Total Operating Expenses | $13.46M | $10.96M | $7.63M | $2.70M |
| D&A | $6.9K | $1.9K | $2.0K | $1.3K |
| Operating Income | ($13.46M) | ($10.96M) | ($7.63M) | ($2.70M) |
| Interest Expense | - | $3.5K | - | $40.2K |
| Income Tax | - | - | - | - |
| Net Income | ($13.24M) | ($10.65M) | ($8.36M) | ($6.71M) |
| EPS - Basic | ($6.64) | ($8.73) | ($9.30) | ($12.75) |
| EPS - Diluted | ($6.64) | ($8.73) | ($9.30) | ($12.75) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash & Equivalents | $4.01M | $10.00M | $8.40M | $32.6K |
| Accounts Receivable | - | - | - | - |
| Inventory | - | - | - | - |
| Accounts Payable | $650.7K | $1.50M | $167.3K | $404.9K |
| Current Assets | $4.32M | $10.11M | $8.49M | $727.6K |
| Total Assets | $4.33M | $10.12M | $8.52M | $778.2K |
| Current Liabilities | $1.59M | $2.68M | $826.9K | $1.33M |
| Long-term Debt | - | - | - | - |
| Total Liabilities | $1.59M | $2.68M | $826.9K | $6.33M |
| Stockholders' Equity | $2.74M | $7.44M | $7.69M | ($5.55M) |
| Retained Earnings | ($38.96M) | ($25.72M) | ($15.07M) | ($6.71M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Cash Flow | ($12.60M) | ($7.36M) | ($3.53M) | ($1.20M) |
| Investing Cash Flow | ($5.1K) | ($6.5K) | ($3.3K) | ($2.3K) |
| Financing Cash Flow | $6.60M | $8.98M | $11.90M | $1.24M |
| CapEx | $5.1K | $6.5K | $3.3K | $2.3K |
| Free Cash Flow | ($12.61M) | ($7.36M) | ($3.53M) | ($1.21M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Profitability | ||||
| Gross margin | - | - | - | - |
| Operating margin | - | - | - | - |
| EBITDA margin | - | - | - | - |
| Net margin | - | - | - | - |
| Free cash flow margin | - | - | - | - |
| FCF / Net income | 0.95 | 0.69 | 0.42 | 0.18 |
| R&D / Revenue | - | - | - | - |
| SG&A / Revenue | - | - | - | - |
| Effective tax rate | - | - | - | - |
| Return on assets | -305.9% | -105.2% | -98.1% | -862.8% |
| Return on equity | -483.3% | -143.2% | -108.6% | 121.0% |
| Return on invested capital | - | - | - | - |
| Liquidity | ||||
| Current ratio | 2.72 | 3.77 | 10.27 | 0.55 |
| Quick ratio | 2.72 | 3.77 | 10.27 | 0.55 |
| Cash ratio | 2.52 | 3.73 | 10.16 | 0.02 |
| Leverage | ||||
| Debt / Equity | - | - | - | - |
| Debt / Assets | - | - | - | - |
| Debt / EBITDA | - | - | - | - |
| Interest coverage | - | -3101.5x | - | -67.2x |
| Equity multiplier | 1.58 | 1.36 | 1.11 | -0.14 |
| Liabilities / Assets | 0.37 | 0.27 | 0.10 | 8.13 |
| Efficiency | ||||
| Asset turnover | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days inventory outstanding | - | - | - | - |
| Days payable outstanding | - | - | 277d | 671d |
| Cash conversion cycle | - | - | - | - |
| Valuation | ||||
| P / E | - | - | - | - |
| P / B | 4.9x | 2.4x | 19.5x | - |
| P / S | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| Growth | ||||
| Revenue growth (YoY) | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - |
| Operating income growth (YoY) | -22.8% | -43.6% | -182.5% | - |
| Net income growth (YoY) | -24.3% | -27.5% | -24.5% | - |
| EPS growth (YoY) | 23.9% | 6.1% | 27.1% | - |
| EPS CAGR (3y) | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - |
| FCF growth (YoY) | -71.2% | -108.4% | -192.7% | - |
| FCF CAGR (5y) | - | - | - | - |
| Book value growth (YoY) | -63.2% | -3.3% | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$200.00M totalRoyalty$200.00M · 100.0%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Cadrenal Therapeutics against the 5 most active filers in the same SIC group.